

# TROMBOPOIETIN RECEPTOR AGONIST TREATMENT IN IDIOPATHIC THROMBOCYTOPENIC PURPURA

M.H. García Lagunar<sup>1</sup>, I. Español Morales<sup>2</sup>, M. Martínez Penella<sup>1</sup>, I. Muñoz García<sup>1</sup>, M.d.R. Gutiérrez Cívicos<sup>1</sup>, E. Ferris Villanueva<sup>1</sup>, R. Guerrero Bautista<sup>1</sup>, A. García Márquez<sup>1</sup>, D. Lacruz Guzmán<sup>1</sup>, M.S. García Simón<sup>1</sup>.  
<sup>1</sup>Hospital General Universitario Santa Lucía, Farmacia Hospitalaria, Cartagena, Spain.  
<sup>2</sup>Hospital General Universitario Santa Lucía, Hematología, Cartagena, Spain.



**BACKGROUND:** Primary Immune Thrombocytopenia (ITP) is a disease characterized by decreased platelet count due to an accelerated platelet destruction and a reduced of platelet production. Romiplostim and eltrombopag are thrombopoietin receptor agonists (TRA) that stimulate platelet production and they constitute a new therapeutic group for this disease.

**PURPOSE:** To evaluate the effectiveness and safety of TRA in patients with ITP in an university general hospital.


**MATERIALS AND METHODS:** Retrospective observational study including patients with ITP who were treated with TRA.

Data collected:

- Age
- Genre
- Previous treatments including splenectomy status
- Duration and response to treatment
- Side effects



**RESULTS:** From October 2009 to July 2014, fourteen patients with ITP were treated with TRA.



## CONCLUSIONS:

- TRA present very high response rates including the possibility of complete remissions and sustained remissions after having stopped the treatment.
- Tolerance of TRA is good although it is important to keep an eye on the appearance of DVT.
- Patients with ITP, despite having received multiple lines of treatment, respond effectively to TRA.